Enzon Hunkers Down, Canceling Spin-Out To Guard Cash
This article was originally published in The Pink Sheet Daily
Executive Summary
Early-stage pipeline could garner licensing deals as clinical work proceeds, with peak burn year ahead.
You may also be interested in...
Second Time A Charm? Enzon Sells Biotech Business To Italian Pharma
One year after a failed effort to sell off its biotech business, Enzon will bring in $300 million by selling its four specialty drugs to Sigma-Tau.
Second Time A Charm? Enzon Sells Biotech Business To Italian Pharma
One year after a failed effort to sell off its biotech business, Enzon will bring in $300 million by selling its four specialty drugs to Sigma-Tau.
Strong Abraxane Cancer Data Promised, But Abraxis Mum On Spin-Off Details
Veteran Merck scientist recruited for personalized-medicine push.